Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Shionogi’s Fetroja Wins China NMPA Approval for Complicated UTIs, Targets Resistant Gram‑Negative Infections

Fineline Cube Jan 20, 2026
Company Drug

Chiesi’s Raxone Begins LHON Treatment in China, First World‑Approved Therapy

Fineline Cube Jan 20, 2026
Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors

Fineline Cube Dec 31, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

MicuRx Pharmaceuticals’ MRX-5 Receives FDA Orphan Drug Designation for NTM Infections

Fineline Cube Dec 30, 2024

Sino-US firm MicuRx Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA)...

Company Deals

Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849

Fineline Cube Dec 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...

Company Drug

CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study

Fineline Cube Dec 30, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced positive results from its pivotal Phase...

Company Drug

argenx’s Vygart Hytrulo Approved in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Dec 30, 2024

Holland-based argenx SE (NASDAQ: ARGX) has announced receiving another indication approval from Japan’s Ministry of...

Company Drug

Daiichi Sankyo’s Datroway Approved in Japan for HR+, HER2- Breast Cancer

Fineline Cube Dec 30, 2024

Japan-based pharmaceutical company Daiichi Sankyo (TYO: 4568) has announced that it has received marketing approval...

Company Drug

MabPharm’s CMAB807 Biosimilar Receives Market Approval in Indonesia and Peru

Fineline Cube Dec 30, 2024

Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the...

Company Deals

Shanghai Ark Biopharmaceutical Partners with Partex to Advance AI-Driven Drug Development

Fineline Cube Dec 30, 2024

China’s Shanghai Ark Biopharmaceutical Co., Ltd. has formed a strategic alliance with Germany-based Partex, an...

Company Deals

Zhongheng Group and Fosun Pharmaceutical Form JV to Boost Overseas Business

Fineline Cube Dec 30, 2024

China-based Zhongheng Group (SHA: 600252) has announced plans to establish a joint venture (JV) with...

Company Drug

BeiGene’s Tevimbra Receives FDA Approval for HER2-Negative Gastric Cancer Treatment

Fineline Cube Dec 30, 2024

China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that the...

Company Deals

Huadong Medicine Partners with SynerK PharmaTech for Hypertension siRNA Drug Development

Fineline Cube Dec 30, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a strategic partnership agreement with SynerK...

Policy / Regulatory

NMPA Releases 87th Batch of Reference Drugs for Generic Quality Consistency

Fineline Cube Dec 30, 2024

The National Medical Products Administration (NMPA) has released the 87th batch of reference drugs for...

Company Drug

Bristol-Myers Squibb’s Opdivo Qvantig Receives FDA Approval for Expanded Indications

Fineline Cube Dec 30, 2024

Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that the US Food and...

Company Drug

HitGen Inc. Initiates Phase II Clinical Trial for HG146 in Adenoid Cystic Carcinoma

Fineline Cube Dec 30, 2024

China-based HitGen Inc. (SHA: 688222) has announced the commencement of the first patient enrollment in...

Company Deals

Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion

Fineline Cube Dec 30, 2024

Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...

Company Deals

Xtalpi Inc. Partners with NCCS and Duke-NUS to Advance AI-Driven Drug Discovery

Fineline Cube Dec 30, 2024

Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...

Company

Danaher Corporation Opens Joint Office in Beijing’s Chaoyang District

Fineline Cube Dec 30, 2024

US-based Danaher Corporation (NYSE: DHR), a leading science and tech services provider, has officially launched...

Company Deals

WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development

Fineline Cube Dec 30, 2024

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Policy / Regulatory

Hainan Free Trade Port Gets Green Light for Temporary Import of Special Medical Foods

Fineline Cube Dec 30, 2024

The State Administration for Market Regulation (SAMR) in China has given its approval in principle...

Company

GenFleet Therapeutics Submits IPO Application to HKEX, Backed by CITIC Securities

Fineline Cube Dec 29, 2024

On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application...

Posts pagination

1 … 182 183 184 … 611

Recent updates

  • Blue Sail’s Lithonic IVL System Wins CE Mark for Coronary Calcified Lesions
  • Shionogi’s Fetroja Wins China NMPA Approval for Complicated UTIs, Targets Resistant Gram‑Negative Infections
  • Chiesi’s Raxone Begins LHON Treatment in China, First World‑Approved Therapy
  • EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform
  • AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Blue Sail’s Lithonic IVL System Wins CE Mark for Coronary Calcified Lesions

Company Drug

Shionogi’s Fetroja Wins China NMPA Approval for Complicated UTIs, Targets Resistant Gram‑Negative Infections

Company Drug

Chiesi’s Raxone Begins LHON Treatment in China, First World‑Approved Therapy

Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.